Scarica l'app Stockscreener
23.53
9.57%
-2.49
Dopo l'orario di chiusura:
23.53
Precedente Chiudi:
$26.02
Aprire:
$24.64
Volume 24 ore:
2.39M
Relative Volume:
3.19
Capitalizzazione di mercato:
$1.01B
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
16.23
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
-3.80%
1M Prestazione:
-5.01%
6M Prestazione:
+1.55%
1 anno Prestazione:
+26.64%
Intervallo 1D:
$22.52
$24.91
Intervallo di 1 settimana:
$22.52
$26.48
Portata 52W:
$19.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Confronta PCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
23.53 | 1.12B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-11-17 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Pacira BioSciences (PCRX) Rating Reiterated as 'Buy' by HC Wainw - GuruFocus
What Analysts Are Saying About Pacira BioSciences Stock - Benzinga
Pacira BioSciences (PCRX) Receives 'Buy' Rating from Needham | P - GuruFocus
Pacira BioSciences Stock Pre-Market (-9.7%): Weak Preliminary 2025 Revenue - Trefis
Will Pacira BioSciences Inc. stock benefit from AI adoptionJuly 2025 Big Picture & Growth Focused Investment Plans - ulpravda.ru
Why Pacira BioSciences Inc. stock remains resilient2025 Big Picture & Detailed Earnings Play Strategies - ulpravda.ru
Signal Recap: Will Pacira BioSciences Inc. stock continue upward momentumJuly 2025 Catalysts & Short-Term High Return Ideas - ulpravda.ru
Pacira BioSciences (PCRX) Shares Dip After Revenue Outlook Cut - GuruFocus
Pacira (PCRX) Reports Strong 2025 Performance, Eyes Future Growt - GuruFocus
Pacira drops after adjusting 2025 revenue below consensus - MSN
Pacira reports record EXPAREL sales with 7% volume growth in Q4 By Investing.com - Investing.com South Africa
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues - The Manila Times
Is Pacira BioSciences Inc. stock dividend yield sustainableJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - ulpravda.ru
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences - markets.businessinsider.com
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Aug Chart Watch: How Pacira BioSciences Inc 82P stock reacts to weak economyQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - moha.gov.vn
Bull of the Day: Pacira BioSciences (PCRX) - MSN
(PCRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
PCRX (Pacira BioSciences) 3-Year FCF Growth Rate : 30.20% (As of Sep. 2025) - GuruFocus
Big and small, Bay Area companies catch eye of activist shareholders at year's endSan Francisco Business Times - The Business Journals
Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale - marketscreener.com
DOMA to nominate three directors to Pacira board, urges company sale By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
DOMA Perpetual Pushes for Strategic Changes at Pacira BioSciences (PCRX) - GuruFocus
Pacira (PCRX) Faces Push for Leadership Change and Strategic Rev - GuruFocus
DOMA to nominate three directors to Pacira board, urges company sale - Investing.com India
Doma Perpetual Capital Management asserts Pacira BioSciences's board to pursue sale of company - MarketScreener
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. - Nasdaq
Pacira BioSciences, Inc. $PCRX Shares Sold by Simplify Asset Management Inc. - MarketBeat
Pacer Advisors Inc. Trims Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
75,598 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Exchange Traded Concepts LLC - MarketBeat
Pacira BioSciences (PCRX): How the New PROBE Consortium Partnership Shapes Its Current Valuation - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Neelam Linens and Garments (India) Limited Benefit From Sector TailwindsConsumer Goods Stocks & Free Stock Index Interpretations - bollywoodhelpline.com
OA Gets a Data-Driven PROBE Makeover - Orthopedics This Week
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How Investors May Respond To Pacira BioSciences (PCRX) Joining AI-Driven PROBE Osteoarthritis Consortium - Sahm
Pacira BioSciences (PCRX) price target decreased by 18.47% to 30.77 - MSN
Price-Driven Insight from (PCRX) for Rule-Based Strategy - Stock Traders Daily
Assenagon Asset Management S.A. Sells 250,594 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Will Pacira BioSciences Inc. stock maintain momentum in 2025Stop Loss & Weekly Breakout Opportunity Watchlist - Улправда
Is Pacira BioSciences Stock Built to Withstand a Pullback? - Trefis
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care - Ortho Spine News
Will Pacira BioSciences Inc. (82P) stock deliver stable dividendsJuly 2025 Rallies & Risk Controlled Stock Alerts - Улправда
How geopolitical tensions affect Pacira BioSciences Inc. stockWeekly Profit Report & Safe Capital Preservation Plans - DonanımHaber
Why Pacira BioSciences Inc. stock remains a top recommendationJuly 2025 PreEarnings & Short-Term High Return Strategies - DonanımHaber
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.37%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):